AI & ML will now speed up the drug development process
Artificial Intelligence and Machine Learning will aid in the process of drug-making by predicting the chance of success of compounds used in drugs.
IBM research and Arctoris are both tying up to bring the power of Artificial Intelligence and robotic automation to the process of developing new drugs. This collaboration can help in making smarter choices early in the process of manufacturing thus making the process faster, and on the other hand, reducing the odds.
IBM research contributed two platforms to this project. The RXN for chemistry uses natural language processing to automate synthetic chemistry and AI to make predictions about the success rate of the compounds used in the medicines. The company also uses an automated platform RoboRXN for molecule synthesis. The other company Arctoris used its automated platform Ulysses for the project which uses robots and digital data to conduct lab experiments in cell biology, molecular biology, and biophysics. And the experiments conducted by Ulysses generated 100 times more data in comparison to the industry-standard manual methods.
Thomas A. Fleming, Arctoris co-founder and COO of the project said:
“This collaboration will showcase how the combination of our unique technology platforms will lead to accelerated research based on better data enabling better decisions.”
Artificial Intelligence in healthcare is doing wonders and has open doors to endless possibilities. It is no doubt that AI has expedited the medical processes eventually making the medical industry faster and efficient. From fighting cancer to detecting brain diseases the importance of AI-powered systems in the healthcare industry cannot be denied at any cost.